首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Guanxinshutong Alleviates Atherosclerosis by Suppressing Oxidative Stress and Proinflammation in ApoE?/? Mice
【24h】

Guanxinshutong Alleviates Atherosclerosis by Suppressing Oxidative Stress and Proinflammation in ApoE?/? Mice

机译:瓜鑫申潼通过抑制氧化应激和促进Apoe的促炎症来减轻动脉粥样硬化?/?老鼠

获取原文
           

摘要

Atherosclerosis (AS) is a chronic progressive disease related to dyslipidemia, inflammation, and oxidative stress. Guanxinshutong capsule (GXST), a traditional Chinese medicine, has been widely used in treating coronary atherosclerotic heart disease, while its mechanism actions on AS are still not to be well addressed. Our present study is aimed to examine the effect of GXST on AS and elucidate the multitarget mechanisms of GXST on AS. Network pharmacology analysis was employed to screen the multitarget mechanisms of GXST on AS. ApoE?/? mice were used to validate these effects. Circulating lipid profile and oxidative stress-related factors were measured by the Elisa kit. Furthermore, the aortic trunk and aortic root were excised for oil red O staining, histopathological and immunohistochemical analysis. We first discovered that GXST was clued to exert synergistically antiatherosclerosis properties including lipid-lowering, anti-inflammation, and antioxidation through the computational prediction based on a network pharmacology simulation. Next, the validation experiments in atherosclerosis mice provided evidence that GXST significantly reduced atherosclerotic lesions, increased collagen deposition, and attenuated LV remodeling to some extent. Mechanistically, GXST modulated lipid profile, downregulated the level of inflammatory cytokines and NF-κBp65. GXST also reduced the activity of oxidative parameter MDA and upregulated the activities of antioxidant enzymes (SOD and GSH) compared with the AS model group. In conclusion, GXST intervention might attenuate atherosclerosis by mechanisms involving reducing lipid deposition, modulating oxidative stress and inflammatory responses, but a larger controlled trial is necessary for confirmation.
机译:动脉粥样硬化(AS)是与血脂血症,炎症和氧化应激相关的慢性渐进性疾病。中药冠新申龙胶囊(GXST)已被广泛用于治疗冠状动脉粥样硬化心脏病,而其机制行动仍未得到很好的解决。我们现在的研究旨在审查GXST的影响,并阐明GXST的多元机制。采用网络药理学分析来筛选GXST的多元机制。 Apoe?/?小鼠用于验证这些效果。通过ELISA试剂盒测量循环脂质曲线和氧化应激相关因子。此外,对油红色O染色,组织病理学和免疫组织化学分析切除主动脉躯干和主动脉根。我们首先发现,通过基于网络药理学模拟的计算预测,GXST被提升,包括脂质降低,抗炎和通过计算预测的抗氧化和抗氧化。接下来,动脉粥样硬化小鼠的验证实验提供了证据表明,GXST显着降低了动脉粥样硬化病变,增加了胶原沉积,并在一定程度上减毒了LV重塑。机械上,GXST调节脂质谱,下调炎症细胞因子和NF-κBP65的水平。 GXST还降低了氧化参数MDA的活性,并上调了与作为模型组相比的抗氧化酶(SOD和GSH)的活性。总之,GXST干预可能通过涉及减少脂质沉积,调节氧化应激和炎症反应的机制来衰减动脉粥样硬化,但是对确认需要更大的对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号